Oncolytic Viruses: Programmable Cancer Killing Machines

John Bell The Ottawa Hospital University of Ottawa


The Ottawa Regional Cancer Foundation

Terry Fox Foundation Canadian Cancer Society Research Institute Ontario Institute for Cancer Research] Canadian Institute for Health Research Prostate Cancer Canada The Ottawa Hospital Foundation 

CHEMOTHERAPY

CANCER <u>TARGETED</u> THERAPIES


Our bodies are made of billions and billions of cells




Viruses are parasites and can only reproduce inside of cells

We have Designed Viruses to be Parasites of Cancer Cells!

Oncolytic Virus Paradigm



Model of Metastatic Cancer





Virus - Lung Metastasis Model




2 weeks following

intravenous tumour cell injection






IV Administer Virus (GREEN) and wait 24 hours



Mouse Experiments can Lead to Therapies for Patients


Vaccinia: A Virus that Selectively Infects and Destroys Tumours: A Cancer Parasite!



Vaccinia Virus: JX-594

Engineered to take advantage of the loss of anti-viral programs and the unregulated metabolism of tumour cells (TK deletions, mutant B18R protein)

Tumour Responses Following Oncolytic Virus: Examples of tumour responses on Phase 1 & Phase 2 trials




This happens in a minority of patients, elite responders!!....How can we make this happen more often?

Oncolytic Viruses Engage the Immune System

Immunity and OV therapy



Implant Colon Tumour







"Cured" mouse wait 7 months Challenge with Colon Cancer cells



Phase | Clinical Trial Metastatic Melanoma: Evidence of Anti-tumour Immunity

32 year-old woman:

- Refractory, widespread met
- Complete tumor regressions:
 - Injected
 - Distant dermal, chest (surg)
- Disease-free 3.5+ years


Pre-treatment




After Virus



Oncolytic Viruses and Immune Checkpoint Inhibitors: Complementary Therapeutics



Combination of Virus Therapy with Immune Activating Agents is Likely to be Most Effective



Pre-Treatment Day 30







immune cells

NFFPC 2004

Bio-Therapy

virus infection & cell lysis

shutting off tumor blood supply

> tumor-targeting antibodies

Research Strategy at the Ottawa Hospital









DISCOVERY

TESTING

